Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

1.

[New oral anticoagulants in the treatment of venous thromboembolic disease].

Calvo Romero JM, Lima Rodríguez EM.

Semergen. 2013 Apr;39(3):146-9. doi: 10.1016/j.semerg.2012.10.007. Epub 2012 Dec 20. Spanish.

PMID:
23540987
[PubMed - indexed for MEDLINE]
2.

New oral anticoagulants for the treatment of venous thromboembolism.

Agnelli G, Becattini C, Franco L.

Best Pract Res Clin Haematol. 2013 Jun;26(2):151-61. doi: 10.1016/j.beha.2013.07.005. Epub 2013 Jul 22. Review.

PMID:
23953903
[PubMed - indexed for MEDLINE]
3.

[New anticoagulants: dabigatran, rivaroxaban and apixaban].

Vargas Ruiz AG, Ramírez López AN, Medina Viramontes ME.

Gac Med Mex. 2012 May-Jun;148(3):257-64. Review. Spanish.

PMID:
22820359
[PubMed - indexed for MEDLINE]
4.

Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.

Friedman RJ.

Orthopedics. 2011 Oct;34(10):795-804. doi: 10.3928/01477447-20110826-24. Review.

PMID:
21956181
[PubMed - indexed for MEDLINE]
5.

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

Loke YK, Kwok CS.

J Clin Pharm Ther. 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x. Review.

PMID:
21198726
[PubMed - indexed for MEDLINE]
6.

[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

Dumont B, Faille D, Ajzenberg N.

Med Sci (Paris). 2011 May;27(5):493-500. doi: 10.1051/medsci/2011275014. Epub 2011 May 25. Review. French.

PMID:
21609670
[PubMed - indexed for MEDLINE]
Free Article
7.

Characteristics of novel anticoagulants and potential economic implications.

Nutescu E.

Am J Manag Care. 2011 Feb;17(1 Suppl):S27-32. Review.

PMID:
21517653
[PubMed - indexed for MEDLINE]
Free Article
8.

Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.

Quinlan DJ, Eriksson BI.

Best Pract Res Clin Haematol. 2013 Jun;26(2):171-82. doi: 10.1016/j.beha.2013.07.003. Epub 2013 Jul 26. Review.

PMID:
23953905
[PubMed - indexed for MEDLINE]
9.

Novel oral anticoagulants: a review of new agents.

Wanat MA.

Postgrad Med. 2013 Jul;125(4):103-14. doi: 10.3810/pgm.2013.07.2683. Review.

PMID:
23933899
[PubMed - indexed for MEDLINE]
10.

[Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism].

Ordovás Baines JP.

Farm Hosp. 2009 May-Jun;33(3):123-4. Spanish. No abstract available.

PMID:
19712595
[PubMed - indexed for MEDLINE]
11.

Long-term benefits of preventing venous thromboembolic events.

Cohen AT.

Curr Med Res Opin. 2012 Jun;28(6):877-89. doi: 10.1185/03007995.2012.688737. Epub 2012 May 24. Review. Erratum in: Curr Med Res Opin. 2012 Sep;28(9):1574. Dosage error in article text.

PMID:
22533680
[PubMed - indexed for MEDLINE]
12.

Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.

Welzel D, Hull R, Fareed J.

Int Angiol. 2011 Jun;30(3):199-211. Review.

PMID:
21617603
[PubMed - indexed for MEDLINE]
13.

Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.

Levi M.

Thromb Haemost. 2012 Aug;108(2):201-2. doi: 10.1160/TH12-05-0330. Epub 2012 Jun 28. No abstract available.

PMID:
22739774
[PubMed - indexed for MEDLINE]
14.

Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

Turpie AG, Kreutz R, Llau J, Norrving B, Haas S.

Thromb Haemost. 2012 Nov;108(5):876-86. doi: 10.1160/TH12-03-0209. Epub 2012 Sep 26. Review.

PMID:
23014816
[PubMed - indexed for MEDLINE]
15.

[New anticoagulants: better knowledge, better prescriptions].

Boehlen F, de Moerloose P.

Rev Med Suisse. 2012 Jan 18;8(324):96-9. French.

PMID:
23185817
[PubMed - indexed for MEDLINE]
16.

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.

Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N.

J Med Econ. 2011;14(2):238-44. doi: 10.3111/13696998.2011.564699. Epub 2011 Mar 9.

PMID:
21385145
[PubMed - indexed for MEDLINE]
17.

["Xa-tra-xa": opportunities and open questions about new anticoagulants].

Beer JH.

Praxis (Bern 1994). 2011 Aug 10;100(16):947. German. No abstract available.

PMID:
21910293
[PubMed - indexed for MEDLINE]
18.

New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.

Tripodi A, Palareti G.

J Intern Med. 2012 Jun;271(6):554-65. doi: 10.1111/j.1365-2796.2012.02541.x. Epub 2012 Apr 19. Review.

PMID:
22443239
[PubMed - indexed for MEDLINE]
19.

New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.

Morris TA.

Clin Chest Med. 2010 Dec;31(4):707-18. doi: 10.1016/j.ccm.2010.06.006. Review.

PMID:
21047577
[PubMed - indexed for MEDLINE]
20.

Newer anticoagulants for the prevention of venous thromboembolism.

Jaggia A.

Natl Med J India. 2012 Jan-Feb;25(1):22-5. Review. No abstract available.

PMID:
22680317
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk